Cargando…
Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers
T follicular helper (T(FH)) cells are powerful regulators of affinity matured long-lived plasma cells. Eliciting protective, long-lasting antibody responses to achieve persistent immunity is the goal of most successful vaccines. Thus, there is potential in manipulating T(FH) cell responses. Herein,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308430/ https://www.ncbi.nlm.nih.gov/pubmed/32612608 http://dx.doi.org/10.3389/fimmu.2020.01213 |
_version_ | 1783548990030086144 |
---|---|
author | Carnathan, Diane G. Kaushik, Kirti Ellebedy, Ali H. Enemuo, Chiamaka A. Gebru, Etse H. Dhadvai, Pallavi Rasheed, Mohammed Ata Ur Pauthner, Matthias G. Ozorowski, Gabriel Ahmed, Rafi Burton, Dennis R. Ward, Andrew B. Silvestri, Guido Crotty, Shane Locci, Michela |
author_facet | Carnathan, Diane G. Kaushik, Kirti Ellebedy, Ali H. Enemuo, Chiamaka A. Gebru, Etse H. Dhadvai, Pallavi Rasheed, Mohammed Ata Ur Pauthner, Matthias G. Ozorowski, Gabriel Ahmed, Rafi Burton, Dennis R. Ward, Andrew B. Silvestri, Guido Crotty, Shane Locci, Michela |
author_sort | Carnathan, Diane G. |
collection | PubMed |
description | T follicular helper (T(FH)) cells are powerful regulators of affinity matured long-lived plasma cells. Eliciting protective, long-lasting antibody responses to achieve persistent immunity is the goal of most successful vaccines. Thus, there is potential in manipulating T(FH) cell responses. Herein, we describe an HIV vaccine development approach exploiting the cytokine activin A to improve antibody responses against recombinant HIV Envelope (Env) trimers in non-human primates. Administration of activin A improved the magnitude of Env-specific antibodies over time and promoted a significant increase in Env-specific plasma cells in the bone marrow. The boost in antibody responses was associated with reduced frequencies of T follicular regulatory (T(FR)) cells and increased germinal center T follicular helper (GC-T(FH)) to T(FR) cell ratios. Overall, these findings suggest that adjuvants inducing activin A production could potentially be incorporated in future rational design vaccine strategies aimed at improving germinal centers, long-lived plasma cells, and sustained antibody responses. |
format | Online Article Text |
id | pubmed-7308430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73084302020-06-30 Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers Carnathan, Diane G. Kaushik, Kirti Ellebedy, Ali H. Enemuo, Chiamaka A. Gebru, Etse H. Dhadvai, Pallavi Rasheed, Mohammed Ata Ur Pauthner, Matthias G. Ozorowski, Gabriel Ahmed, Rafi Burton, Dennis R. Ward, Andrew B. Silvestri, Guido Crotty, Shane Locci, Michela Front Immunol Immunology T follicular helper (T(FH)) cells are powerful regulators of affinity matured long-lived plasma cells. Eliciting protective, long-lasting antibody responses to achieve persistent immunity is the goal of most successful vaccines. Thus, there is potential in manipulating T(FH) cell responses. Herein, we describe an HIV vaccine development approach exploiting the cytokine activin A to improve antibody responses against recombinant HIV Envelope (Env) trimers in non-human primates. Administration of activin A improved the magnitude of Env-specific antibodies over time and promoted a significant increase in Env-specific plasma cells in the bone marrow. The boost in antibody responses was associated with reduced frequencies of T follicular regulatory (T(FR)) cells and increased germinal center T follicular helper (GC-T(FH)) to T(FR) cell ratios. Overall, these findings suggest that adjuvants inducing activin A production could potentially be incorporated in future rational design vaccine strategies aimed at improving germinal centers, long-lived plasma cells, and sustained antibody responses. Frontiers Media S.A. 2020-06-16 /pmc/articles/PMC7308430/ /pubmed/32612608 http://dx.doi.org/10.3389/fimmu.2020.01213 Text en Copyright © 2020 Carnathan, Kaushik, Ellebedy, Enemuo, Gebru, Dhadvai, Rasheed, Pauthner, Ozorowski, Ahmed, Burton, Ward, Silvestri, Crotty and Locci. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Carnathan, Diane G. Kaushik, Kirti Ellebedy, Ali H. Enemuo, Chiamaka A. Gebru, Etse H. Dhadvai, Pallavi Rasheed, Mohammed Ata Ur Pauthner, Matthias G. Ozorowski, Gabriel Ahmed, Rafi Burton, Dennis R. Ward, Andrew B. Silvestri, Guido Crotty, Shane Locci, Michela Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title | Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title_full | Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title_fullStr | Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title_full_unstemmed | Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title_short | Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers |
title_sort | harnessing activin a adjuvanticity to promote antibody responses to bg505 hiv envelope trimers |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308430/ https://www.ncbi.nlm.nih.gov/pubmed/32612608 http://dx.doi.org/10.3389/fimmu.2020.01213 |
work_keys_str_mv | AT carnathandianeg harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT kaushikkirti harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT ellebedyalih harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT enemuochiamakaa harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT gebruetseh harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT dhadvaipallavi harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT rasheedmohammedataur harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT pauthnermatthiasg harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT ozorowskigabriel harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT ahmedrafi harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT burtondennisr harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT wardandrewb harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT silvestriguido harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT crottyshane harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers AT loccimichela harnessingactivinaadjuvanticitytopromoteantibodyresponsestobg505hivenvelopetrimers |